Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc > Reddit MMED has 30% of float shorted. Interest 35%

<< Previous

Bullboard Posts

Next >>

Comment by Bubbsy2014on Jan 28, 2021 7:21pm

226 Views

Post# 32416168

RE:RE:Reddit MMED has 30% of float shorted. Interest 35%

You spew nonsense dude. You don’t have the margin to short anything nor know how too? You live a sorry pathetic life. Maybe Mmed micro dose can help? Probably too far gone? Don’t listen to him. Yes, Mmed was shorted significantly. That’s not a sell. It’s what happens when market makers want to make short money. It’s not investors losing faith. Keep it. Don’t sell. Bubbs.

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market